Analyst Ratings for [BHVN] Biohaven Pharmaceutical Holding Company Ltd.

2/11/25	Initiated	Buy	X
BHVN Biohaven Deutsche Bank
$65
9/16/24	Initiated	Buy	X
BHVN Biohaven Jefferies
$57
9/4/24	Initiated	Outperform	X
BHVN Biohaven Bernstein
$55
7/24/24	Initiated	Overweight	X
BHVN Biohaven Morgan Stanley
$58
2/16/24	Initiated	Outperform	X
BHVN Biohaven RBC Capital Mkts
$62
2/6/24	Initiated	Buy	X
BHVN Biohaven UBS
$59
12/22/23	Initiated	Buy	X
BHVN Biohaven H.C. Wainwright
$50
12/8/23	Initiated	Outperform	X
BHVN Biohaven Robert W. Baird
$58
1/24/23	Initiated	Outperform	X
BHVN Biohaven SVB Securities
$24
1/4/23	Initiated	Overweight	X
BHVN Biohaven JP Morgan
$23
12/2/22	Initiated	Buy	X
BHVN Biohaven BTIG Research
$24
10/26/22	Upgrades	Neutral Overweight	X
BHVN Biohaven Cantor Fitzgerald
$158 $27
10/12/22	Initiated	Overweight	X
BHVN Biohaven Piper Sandler
$23
8/19/22	Downgrades	Overweight Neutral	X
BHVN Biohaven Pharmaceutical Piper Sandler
$149
8/8/22	Downgrades	Outperform Neutral	X
BHVN Biohaven Pharmaceutical Wedbush
$148.50
5/11/22	Downgrades	Outperform Mkt Perform	X
BHVN Biohaven Pharmaceutical SVB Leerink
$150
10/19/21	Resumed	Equal-Weight	X
BHVN Biohaven Pharmaceutical Morgan Stanley
$107 $145
3/11/21	Initiated	Buy	X
BHVN Biohaven Pharmaceutical UBS
$108
6/25/19	Reiterated	Buy	X
BHVN Biohaven Pharmaceutical Canaccord Genuity
$89 $84
5/6/19	Initiated	Buy	X
BHVN Biohaven Pharmaceutical Goldman
$92
4/9/19	Downgrades	Overweight Eq-Weight	X
BHVN Biohaven Pharmaceutical Morgan Stanley
3/4/19	Reiterated	Buy	X
BHVN Biohaven Pharmaceutical Needham
$48 $56
7/3/18	Reiterated	Buy	X
BHVN Biohaven Pharmaceutical Needham
$36 $48
7/2/18	Reiterated	Buy	X
BHVN Biohaven Pharmaceutical Needham
$36 $48
4/5/18	Downgrades	Overweight Eq Weight	X
BHVN Biohaven Pharmaceutical Barclays
$30 $25
2/22/18	Reiterated	Buy	X
BHVN Biohaven Pharmaceutical Canaccord Genuity
$30 $39

BHVN Biohaven Pharmaceutical Holding Company Ltd.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates. Its pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity (NCE) that modulates glutamate, and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate (NMDA) receptor antagonism. Its clinical compound, trigriluzole, is indicated for neurodegenerative diseases and cancer indications, among others. Its pipeline also includes BHV-3000 and BHV-3500, which are in-licensed by the Company for a neurologic indication. It focuses on advancing other mechanistic approaches in orphan and neuroscience indications, and is exploring licenses for additional compounds.